INS and type 1 diabetes mellitus: Furthermore, the addition of liraglutide (a GLP-1 receptor agonist) to insulin therapy has also demonstrated potential benefits including but not limited to reduced HbA1c level, body weight, and insulin requirement in T1D patients (49, 61–63).